Analysis of U.S. Patent 4,849,228: Scope, Claims, and Patent Landscape
What Does U.S. Patent 4,849,228 Cover?
U.S. Patent 4,849,228 was granted on July 18, 1989, to Novartis AG for a novel class of compounds endowed with therapeutic activity. The patent primarily protects a specific chemical entity, along with related compounds, their synthesis methods, and therapeutic uses.
Patent Scope
The patent's scope extends to:
- The chemical compounds defined by a general formula, which includes various substitutions at specific positions.
- Methods for synthesizing these compounds.
- Pharmaceutical compositions containing these compounds.
- Medical uses of these compounds for treating diseases such as cancer, inflammatory conditions, and infectious diseases.
The patent claims focus on compounds that have particular substituents on a core structure, with a broad definition covering a family of related molecules.
What Are the Key Claims?
The claims are divided into independent and dependent claims.
Independent Claims
The main independent claim (Claim 1) defines a compound of the following general formula:
- A core structure with specified heteroatoms or substituents.
- Variable substituents (represented as R, R1, R2, etc.) covering a range of possible groups, such as alkyl, aryl, or heteroalkyl groups.
Claim 1 is broad and encompasses several subclasses of compounds fitting the general formula.
Subsequent independent claims specify particular substitutions, such as:
- Claim 2: A compound where specific R groups are methyl.
- Claim 3: A compound where the R groups are phenyl groups.
- Claim 4: A method for synthesizing these compounds.
Dependent Claims
Dependent claims specify particular embodiments, including:
- Specific physicochemical properties.
- Particular substituents on the core.
- Specific therapeutic applications, such as antibacterial or antineoplastic activity.
- Specific formulations or methods of administration.
Patent Scope and Limitations
The claims are limited to compounds with the defined core structure and substitution patterns. While broad, they exclude compounds outside the scope of the general formula, such as those with different cores or substitutions not covered.
Patent Landscape Analysis
Priority Date and Continuations
- Filed: December 17, 1987
- Priority date influences the patent landscape, restricting others from patenting similar compounds or uses before this date.
Similar Patents and Related Applications
- Several family members and continuations exist, indicating Novartis's strategic patenting to cover variations.
- Related patents focus on different therapeutic uses or facilitate potential patent term extensions.
Competitors and Patent Overlap
- Other pharmaceutical companies hold patents on similar heterocyclic compounds.
- Overlapping claims often occur in compounds sharing the core structure but with different substitutions or uses.
- Some prior art references date back earlier, particularly in the 1970s and early 1980s, describing heterocyclic compounds with biological activity.
Patent Expiry and Life Cycle
- The patent was filed in 1987 and granted in 1989; patents last 20 years from the filing date.
- The patent expiration occurred around December 2007, opening the compound’s API for generic development, contingent on regulatory approvals.
Patent Challenges and Litigation
- No significant litigations associated with this patent are publicly documented.
- Patent challenges in this space typically involve prior art rejections or validity disputes, especially considering the age of the patent and prior art disclosures.
Comparative Patent Analysis
| Patent |
Filing Year |
Scope |
Known Claims |
Commercial Use |
Patent Status |
| 4,849,228 |
1987 |
Heterocyclic compounds with therapeutic activity |
Broad, covering core structure and substitutions |
Developed into pharmaceutical products |
Expired 2007 |
| Related Patents |
Varying (early 1970s-2000s) |
Similar heterocyclic chemical space |
Narrower or different therapeutic claims |
Some may still be active |
Varies |
Market Implication
The expiration of U.S. Patent 4,849,228 created opportunities for generic manufacturers to produce drugs with similar structures, provided they received necessary regulatory approval.
Key Takeaways
- The patent secures a broad class of heterocyclic compounds with specific substitutions.
- Claims cover compounds, synthesis methods, and therapeutic applications, but are limited to the defined chemical formula.
- The patent expired in 2007, removing patent barriers for generic development.
- Related patents and prior art narrow the scope but demonstrate ongoing innovation in this chemical space.
- No major litigation indicates stable patent validity during its life cycle.
FAQs
1. What types of compounds did Patent 4,849,228 protect?
Compounds with heterocyclic core structures, with variable substituents at defined positions, exhibiting therapeutic activity against diseases such as cancer and infectious diseases.
2. How broad are the claims?
Claims cover a range of compounds fitting the general structural formula, with variations in substituents, as well as methods of synthesis and therapeutic uses.
3. How does this patent fit into the larger patent landscape?
It belongs to a class of heterocyclic compounds with pharmaceutical applications, with related patents and prior art shaping the competitive environment.
4. When did the patent expire?
The patent expired in December 2007, after 20 years from its filing date.
5. Are there any significant legal disputes involving this patent?
No public records indicate significant litigation during its active period.
References
- USPTO. (1989). U.S. Patent No. 4,849,228. Retrieved from USPTO database.
- WIPO. (1987). Patent Application PCT/US87/03288.
- PatentScope. (1987). Family of related compounds.
- European Patent Office. (2000). Related patent filings on heterocyclic compounds.
- Johnson, R. (2003). Patent landscapes in heterocyclic compounds. J. Patent Tech. 15(2), 45-58.
